NCT07695207招募中3 期
A 12-month, Randomization, Double-blind, Placebo-controlled, Parallel, Multicenter-Phase 3 Trial to Evaluate the Safety and Efficacy of SMZ1 Tablet in Combination With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
SANGMYUNG innovation1 个研究点 分布在 1 个国家目标入组 266 人开始时间: 2025年9月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 266
- 试验地点
- 1
- 主要终点
- Best corrected visual acuity (BCVA) at Month 12
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of SMZ1 tablets in combination with Ranibizumab compared with placebo in combination with Ranibizumab in subjects with neovascular (wet) age-related macular degeneration (nAMD) without polypoidal choroidal vasculopathy (PCV). The primary objective is to demonstrate the superiority of SMZ1 tablets over placebo with respect to improvement in best-corrected visual acuity at Month 12.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •50 years of age or older
- •A study eye satisfying all of the following criteria after screening
- •① Active* submacular choroidal neovascularization due to nAMD confirmed by fluorescein angiography (FAG) and optical coherence tomography (OCT)
- •*Fluorescence leakage confirmed via FAG and intraretinal or subretinal fluid confirmed via OCT
- •② Absence of active polypoidal lesions due to polypoidal choroidal vasculopathy (PCV) confirmed by indocyanine green angiography (ICGA)
- •A study eye with fibrosis covering less than 50% of the total lesion area
- •A study eye with ETDRS best corrected visual acuity (BCVA) score range of 73-24 at a distance of 4m (equivalent to 20/40-20/320 of Snellen)
- •A study eye with a neovascular lesion area of less than 12 optic-disk areas (For an optic nerve head diameter set to 1.8mm, the corresponding optic-disk area is 2.45mm2)
- •Provided written informed consent voluntarily after receiving a full explanation of the clinical trial.
排除标准
- •History of ocular treatment, systemic therapies, or surgical procedures, such as photodynamic therapy (PDT) and laser photocoagulation, for the treatment of wet nAMD (supplements and vitamins excluded)
- •History of anti-VEGF treatment (e.g., ranibizumab, bevacizumab, aflibercept 2mg, or biosimilars) or combination therapy in the study eye for the treatment of wet nAMD
- •A study eye with scarring or fibrosis covering more than 50% of the total lesion area
- •A study eye with vitreous hemorrhage occurring within 1 month prior to the Screening Visit
- •A study eye with intraocular pressure (IOP) ≥ 25mmHg, including glaucoma with IOP ≥ 25mmHg despite medical treatment
- •A study eye with a total lesion area (including vessels, scar tissue, and neovascularization) greater than 12 optic-disk areas (>30.5mm2), as measured by FAG
结局指标
主要结局
Best corrected visual acuity (BCVA) at Month 12
时间窗: Month 12
Change in BCVA score from baseline, at Month 12 after the administration of the investigational drug using early treatment diabetic retinopathy study (ETDRS) chart
次要结局
- Monthly BCVA(Monthly for 11 months)
- Central retinal thickness (CRT) every three months(Month 3, 6, and 12)
- Ranibizumab retreatment(Through Month 4 and 12)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Efficacy and Safety of APSTZD in the Treatment of Insomnia DisorderInsomniaNCT07420816Apsen Farmaceutica S.A.222
尚未招募
2 期
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax MalariaMalariaNCT07430592R. Kiplin Guy104
招募中
2 期
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced FibrosisHepatic CirrhosisNCT07610837AstraZeneca104
尚未招募
不适用
A clinical trail to Check if Magnetic Devices Can Safely and Effectively Reconnect Blocked or Disconnected Bile Ducts After Gallbladder Surgery or Liver Transplant.CTRI/2025/08/093837Dr Sanjay Raput20
招募中
2 期
A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)NCT07294365Dizal Pharmaceuticals60